![Corcept Therapeutics Incorporated [CORT] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/CORT_b35c00a42d.png)
Corcept Therapeutics Incorporated [CORT] Securities Class Action Lawsuit Update
Corcept Therapeutics (CORT): When FDA Confidence Collided with Regulatory Reality
![Franklin BSP Realty Trust, Inc. [FBRT] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/FBRT_4c120ff401.png)
Franklin BSP Realty Trust: Dividend Promises Collapse Into Reality
Learn about securities lawsuits tied to your portfolio and recover money!
Franklin BSP Realty Trust, Inc. (NYSE: FBRT) told investors its $0.355 quarterly dividend was supportable. A newly filed complaint alleges that message was misleading.
A securities class action filed in the United States District Court for the Eastern District of New York alleges that FBRT and its senior executives misled investors about the sustainability of its $0.355 quarterly dividend and the underlying earnings power supporting it. The complaint centers on the allegation that management projected confidence in dividend coverage and earnings power while the company’s reported results continued to fall short of that $0.355 payout.
According to the complaint, the company’s February 2026 disclosures marked a turning point. A dividend cut. A reset narrative. A stock drop. And now, litigation.
“Most FBRT shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
FBRT operates as a real estate investment trust focused on originating and managing commercial real estate debt across the United States. Its business model depends heavily on income generation and distribution. Investors buy REITs for yield. That is the bargain.
During the Class Period, management repeatedly told investors that dividend coverage would improve as REO assets were resolved, capital was redeployed, and earnings normalized. Management also pointed to NewPoint as a future earnings contributor, including through origination scale, servicing integration, and platform synergies, as part of its path-to-coverage narrative.
But REIT math is unforgiving. Cash flow either covers the dividend, or it doesn’t.
FBRT’s leadership consistently reassured investors that dividend coverage was within reach. On earnings calls, executives framed underperformance as temporary noise rather than structural weakness.
Management stated that the dividend “accurately reflects our portfolio’s long-term stabilized earnings potential” and expressed confidence that earnings would soon align with distributions. The explanation centered on transitional factors. REO assets would be sold. Capital would be redeployed. Earnings would normalize.
The narrative repeated itself quarter after quarter. A path to coverage. A pipeline of improvements. A future that always seemed one or two quarters away. According to the complaint, that future never arrived.
Instead, plaintiffs allege that defendants “recklessly overstated” both the company’s earnings prospects and its ability to maintain the dividend. Plaintiffs allege that the gap between distributable earnings and dividend obligations was not merely temporary and that defendants overstated the company’s ability to maintain the dividend. Plaintiffs allege this was material to investors relying on yield.
The company’s earnings repeatedly fell short of the dividend during the Class Period, according to the complaint and the company’s own cited call statements.
The story unfolds in a familiar cadence. Assurances first. Corrections later.
In November 2024 and February 2025, management acknowledged that earnings did not fully cover the dividend, but insisted that future performance would close the gap. By mid-2025, executives outlined specific drivers expected to restore coverage, including CLO refinancing, REO asset sales, and contributions from NewPoint.
Through 2025, the message remained consistent. Progress was being made. Coverage was coming.
Then February 2026.
On February 10, 2026, the company announced a leadership transition, replacing CEO Richard Byrne with President Michael Comparato. The market reacted cautiously. The stock dipped modestly.
The following day, the real disclosure arrived. Fourth quarter results revealed declining earnings and a fundamental shift in strategy. Management admitted that it had been “over-distributing capital to investors” and announced a dividend cut from $0.355 to $0.20 per share.
Plaintiffs allege that this disclosure revealed the extent of the dividend coverage issues during the Class Period. On February 12, 2026, shares fell approximately 14.18%, closing at $8.71. The correction was immediate. The narrative was over.
On February 10, 2026, FBRT announced a leadership transition, and the stock fell 0.97% on February 11, 2026. The following day, after FBRT disclosed lower earnings, said it had been ‘over-distributing capital to investors,’ and reset the quarterly dividend to $0.20, the stock fell $1.44 per share, or 14.18%, to close at $8.71. The complaint alleges those disclosures revealed the truth about dividend coverage and earnings power.
The action, Moses v. Franklin BSP Realty Trust, Inc. et al., was filed in the Eastern District of New York under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The complaint alleges that FBRT and its executives, including Richard J. Byrne, Jerome S. Baglien, and Michael Comparato, disseminated materially false and misleading statements regarding dividend sustainability and earnings power.
The complaint alleges that senior executives had access to information concerning dividend sustainability, earnings coverage, and portfolio performance, and that they knew or recklessly disregarded that their public statements lacked a reasonable basis. The theory follows a familiar securities litigation framework. Misstatements inflated the stock price. Investors relied on those statements. Corrective disclosures triggered losses.
Control person liability under Section 20(a) is also asserted against individual defendants, based on their roles in overseeing company disclosures and operations.
The case now enters the procedural phase where motions to dismiss, discovery battles, and potential class certification will shape its trajectory.
Retail investor reaction following the dividend reset appears to have been negative, with public commentary focusing on the long-running gap between distributable earnings and the $0.355 dividend, the delayed path to coverage management had described, and the significance of the cut to $0.20 for income-oriented holders. To remain low risk, this section should avoid unattributed quotes and should only include sentiment that is directly hyperlinked to identifiable posts or articles.
Public commentary following FBRT’s February 2026 disclosures focused on the dividend reset, lower earnings, and management’s statement that the company had been “over-distributing capital to investors.” Coverage also centered on whether FBRT could rebuild sustainable dividend coverage through book-value stabilization, REO resolution, and contributions from NewPoint. To keep this section accurate, it should avoid attributing motives or a sell-side “consensus” unless those views are directly sourced and hyperlinked.
FBRT’s public filings during the Class Period acknowledged certain risks, including exposure to real estate market cycles, interest rate volatility, and the timing of asset redeployment. However, the complaint argues that these generalized risk disclosures failed to capture the magnitude and immediacy of the dividend coverage issue.
Earnings calls and SEC disclosures emphasized long-term earnings potential while downplaying the persistent gap between distributable earnings and dividend obligations. In February 2026, management said REO liquidations were taking longer than originally anticipated, that spreads were at multi-decade tights, and that the timing of originations and repayments had affected short-term returns.
Risk factors, in hindsight, read differently when the risk has already materialized.
FBRT’s case sits at the intersection of yield, narrative, and accountability.
Dividend sustainability is not a cosmetic metric. It is the foundation of the REIT investment thesis. When management signals confidence in that foundation, investors listen. When that confidence is later challenged by disclosures, the consequences can unfold quickly.
The lesson is not subtle. Watch coverage ratios. Question forward-looking assurances. Pay attention when “temporary” issues persist across multiple quarters.
Because eventually, the market forces a reconciliation. And when it does, it rarely negotiates.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
![Corcept Therapeutics Incorporated [CORT] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/CORT_b35c00a42d.png)
Corcept Therapeutics (CORT): When FDA Confidence Collided with Regulatory Reality
![Aquestive Therapeutics Inc [AQST] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/AQST_862055633d.png)
Aquestive Therapeutics (AQST) faces a class action alleging it misled investors about Anaphylm’s FDA approval timeline while concealing deficiencies that led to delays and a sharp stock drop.
![Zynex, Inc. [ZYXIQ] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/ZYXIQ_4ed31fe982.png)
Allegations of Fraudulent Billing and Inflated Growth